Treatment of Shiga toxin-producing Escherichia coli infections.

@article{Davis2013TreatmentOS,
  title={Treatment of Shiga toxin-producing Escherichia coli infections.},
  author={Thomas Keefe Davis and Ryan S McKee and David Schnadower and Phillip I. Tarr},
  journal={Infectious disease clinics of North America},
  year={2013},
  volume={27 3},
  pages={
          577-97
        }
}
View on PubMed
doi.org
54 Citations
Highly Influential Citations
5
Background Citations
20
Methods Citations
2
Results Citations
1

54 Citations

Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives.

The best management of E. coli infections consists of avoiding antibiotics, antimotility agents, and narcotics and implementing aggressive intravenous volume expansion, especially in the early phases of illness.

Province‐Wide Review of Pediatric Shiga Toxin‐Producing Escherichia coli Case Management

Prodromal Phase of Hemolytic Uremic Syndrome Related to Shiga Toxin–Producing Escherichia coli

Evaluated practice patterns during prodromal phase of hemolytic uremic syndrome related to Shiga toxin–producing Escherichia coli (STEC-HUS) outlined the critical need to improve the early management of STEC- HUS.

Shiga Toxin Producing Escherichia coli.

Potentiation of Antibiotics by a Novel Antimicrobial Peptide against Shiga Toxin Producing E. coli O157:H7

Proof of principle is provided for the design of an antibiotic-peptide wrwycr combination effective in killing STEC without enhancing release of Shiga toxins.

Postinfectious Hemolytic Uremic Syndrome

Treatment of STEC-HUS is supportive; more investigations are needed to evaluate the efficacy of putative preventive and therapeutic measures, such as non-phage-inducing antibiotics, volume expansion and anti-complement agents.

Antimicrobial Mechanisms of Escherichia coli

This chapter reviews the major strains of E. coli (intestinal and urinary), along with a review of the virulence factors, main diseases caused, and pertinent pathogenesis, and the molecular aspects of antimicrobial resistance mechanisms in this organism are discussed.

Genetic makeup of Shiga toxin-producing Escherichia coli in relation to clinical symptoms and duration of shedding: a microarray analysis of isolates from Swedish children

Genes associated with the duration of stx shedding were detected, enabling a possible better prediction of length of STEC carriage after infection and finding STEC genes that might predict severe disease outcome already at diagnosis.

Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial Ghosts

Development of Gb3 receptor mimic bacterial ghosts (BGs) that are not classified as GMOs offer a non-GMO approach to treatment of STEC infection in humans, particularly in an outbreak setting.

Prevalence and antibiotic resistance profile of Shiga toxin-producing Escherichia coli isolated from diarrheal samples

The results of the current study showed that although the prevalence of E. coli O157: H7 was low among patients with diarrhea, the other STEC strains with relative resistance to antibiotics are more prevalent.
...

References

SHOWING 1-10 OF 101 REFERENCES

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome

Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation.

The presence of EHEC O26:H11 was significantly associated with young age at the disease onset and the importance of implementation of appropriate diagnostic methods to identify the whole spectrum of EhEC associated with HUS is emphasized.

Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4.

Treatment with azithromycin was associated with a lower frequency of long-term STEC O104:H4 carriage, and no recurrence of STEC was observed in patients with HUS and outpatients without manifestation of HUS.

Antibiotic Treatment of Escherichia coli O157 Infection and the Risk of Hemolytic Uremic Syndrome, Minnesota

The use of bactericidal antibiotics, particularly &bgr;-lactams, to treat O157 infection was associated with the subsequent development of HUS.

Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.

The fecal Stx type did not correlate with the Stx expressed by bacteria grown in vitro and was not related to bacterial titer in the studied samples, suggesting that therapeutic and diagnostic strategies directed toward binding or identifying intraintestinal fecalStx may have limited success.

Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection.

The early use of fosfomycin within the first two days of illness might prevent the development of HUS.

Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles.

There were no significant associations between stx genotype and bloody diarrhea, but isolates containing stx2c or stx(2d-activatable) were recovered more often from patients who underwent diagnostic or therapeutic procedures, and non-O157:H7 STEC are more heterogeneous and cause bloody diarrhea less frequently than do E. coli O157: H7.

Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

This large study in children with HUS underlines the rising importance of non-O157:H7 serotypes, and, despite increased public awareness, the number of patients remained unchanged.

Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology.

The culture-positive group was more likely to have had bloody diarrhea and fecal leukocytes and to have received transfusions than the culture-negative group but was otherwise similar in clinical characteristics.

Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.

  • A. FriedrichWenlan Zhang H. Karch
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
Strains of stx-negative E. coli O157 isolated from stool samples of patients are either inherently stx -negative strains that cause mostly uncomplicated diarrhea, or strains that descended from enterohemorrhagic E.coli O157 by the loss of the stx gene during infection; the latter strains may still cause severe disease.
...